In the current study, we used anti-CCL20 antibody to investigate tumor growth in vivo and found that blockade of CCL20 suppressed tumor progression and restored 5-FU sensitivity in CRC, suggesting that the FOXO1/CEBPB/NF-κB/CCL20 axis may be a potential therapeutic target for CRC. The gene discussed is FOXO1; the disease is neoplasm.